Entrada Therapeutics Inc (TRDA)

03:44 AM

Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

03:44 AM

May 05, 2025

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com

May 05, 2025

May 05, 2025

Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace

May 05, 2025

May 05, 2025

Invesco Ltd. Takes Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 05, 2025

May 05, 2025

Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday - Defense World

May 05, 2025

May 01, 2025

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for - MSN

May 01, 2025

May 01, 2025

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive

May 01, 2025

May 01, 2025

Legal & General Group Plc Has $344,000 Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 01, 2025

Apr 30, 2025

Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News

Apr 30, 2025

Apr 30, 2025

JPMorgan Chase & Co. Raises Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 30, 2025

Apr 29, 2025

Entrada Therapeutics IncApproves Strategic Plan Focusing On DMD ProgramsSEC Filing - marketscreener.com

Apr 29, 2025

Apr 27, 2025

Russell Investments Group Ltd. Raises Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 27, 2025

Apr 23, 2025

Geode Capital Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 23, 2025

Apr 21, 2025

LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 21, 2025

Apr 19, 2025

Trend Tracker for (TRDA) - news.stocktradersdaily.com

Apr 19, 2025

Apr 16, 2025

Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 16, 2025

Apr 15, 2025

CandE Benchmark Research Case Study – Entrada Therapeutics - ere.net

Apr 15, 2025

Apr 13, 2025

KLP Kapitalforvaltning AS Invests $36,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 13, 2025

Apr 11, 2025

American Century Companies Inc. Purchases 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Apr 11, 2025

Apr 10, 2025

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance

Apr 10, 2025

Apr 05, 2025

HC Wainwright Issues Negative Forecast for TRDA Earnings - MarketBeat

Apr 05, 2025

Apr 04, 2025

Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop - simplywall.st

Apr 04, 2025

Apr 04, 2025

HC Wainwright Issues Pessimistic Forecast for TRDA Earnings - Defense World

Apr 04, 2025

Apr 03, 2025

(TRDA) On The My Stocks Page - news.stocktradersdaily.com

Apr 03, 2025

Apr 01, 2025

Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025

Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks

Mar 31, 2025

Mar 31, 2025

Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK

Mar 31, 2025

Mar 28, 2025

Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK

Mar 28, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Mar 28, 2025

Mar 24, 2025

Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada

Mar 24, 2025

Mar 24, 2025

Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView

Mar 24, 2025

Mar 24, 2025

Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics begins Duchenne study in UK - Investing.com India

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks

Mar 24, 2025

Mar 24, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times

Mar 24, 2025

Mar 24, 2025

Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan

Mar 24, 2025

Mar 23, 2025

Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Mar 23, 2025

Mar 21, 2025

Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com

Mar 21, 2025

Mar 21, 2025

Entrada Therapeutics stock hits 52-week low at $10.21 By Investing.com - Investing.com UK

Mar 21, 2025

Mar 19, 2025

Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India

Mar 19, 2025

Mar 13, 2025

Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com

Mar 13, 2025

Mar 11, 2025

Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com

Mar 11, 2025

Mar 05, 2025

Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World

Mar 05, 2025

Mar 04, 2025

Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada

Mar 04, 2025

Mar 04, 2025

Brokers Offer Predictions for TRDA Q4 Earnings - Defense World

Mar 04, 2025

Mar 03, 2025

What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World

Mar 03, 2025